TMO supply chain intelligence for Thermo Fisher Scientific Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CLARIO-HOLDINGS-INC | CLARIO-HOLDINGS-INC | 92% | With the transaction complete, the Clario business will become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment. |
| BTAI | BioXcel Therapeutics, Inc. | 85% | Reciprocal relationship from BTAI graph: lization of our products or to produce our products in accordance with cGMP prescribed by the FDA or similar foreign requirements. Drug manufacturing faciliti… |
| ICLR | ICON Public Limited Company | 85% | Reciprocal relationship from ICLR graph: Reciprocal relationship from TMO graph: Reciprocal relationship from ICLR graph: responsibility for the maintenance of key client relationships. Our aim is to… |
| IMTX | Immatics N.V. | 85% | Reciprocal relationship from IMTX graph: A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scientific Inc., for certain manufacturing and quality control services. The Agreement … |
| IONS | Ionis Pharmaceuticals, Inc. | 85% | Reciprocal relationship from IONS graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IONS graph: vestigators, contract research organizations and other third-party service pr… |
| AZTA | Azenta, Inc. | 72% | Reciprocal relationship from AZTA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from AZTA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from AZTA gra… |
| DNA | Ginkgo Bioworks Holdings, Inc. | 72% | Reciprocal relationship from DNA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from DNA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from DNA graph:… |
| GH | Guardant Health, Inc. | 72% | Reciprocal relationship from GH graph: r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we ar… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | Reciprocal relationship from HRMY graph: Reciprocal relationship from TMO graph: Reciprocal relationship from HRMY graph: Reciprocal relationship from TMO graph: Reciprocal relationship from HRMY gra… |
| IDXG | Interpace Biosciences, Inc. | 72% | Reciprocal relationship from IDXG graph: tests from sole suppliers. We also purchase components used in our collection kits from sole-source suppliers. Some of these items are unique to these supplie… |
| IDXX | IDEXX Laboratories, Inc. | 72% | Reciprocal relationship from IDXX graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IDXX graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IDXX gra… |
| IQV | IQVIA Holdings Inc. | 72% | Reciprocal relationship from IQV graph: ies, account for the majority of our revenues. Nearly all of the top 100 global pharmaceutical and biotechnology companies, measured by revenues, are clients, … |
| MEDP | Medpace Holdings, Inc. | 72% | Reciprocal relationship from MEDP graph: Reciprocal relationship from TMO graph: Reciprocal relationship from MEDP graph: d and disciplined approach facilitates strong account evaluation, which resul… |
| MXCT | MaxCyte, Inc. | 72% | Reciprocal relationship from MXCT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from MXCT gra… |
| PACB | Pacific Biosciences of California, Inc. | 72% | Reciprocal relationship from PACB graph: We manufacture sequencing instruments, SMRT Cells, and reagents. Our key manufacturing and service facility in Menlo Park, California has received ISO 13485 a… |
| RGEN | Repligen Corporation | 72% | Reciprocal relationship from RGEN graph: Reciprocal relationship from TMO graph: Reciprocal relationship from RGEN graph: Reciprocal relationship from TMO graph: Reciprocal relationship from RGEN gra… |
| SOLV | Solventum Corporation | 72% | Reciprocal relationship from SOLV graph: Item 1A "Risk Factors" for additional information. Management’s Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed … |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: d other specialized health care providers in the U.S. in the Parkinson's area. Another sales force focuses on psychiatrists, pediatricians, primary care physi… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: ies, Inc., Eurofins Genomics Blue Heron, Elegen Corporation, Ansa Biotechnologies, Inc., Telesis Bio, Inc. and others. Additionally, we compete with both larg… |
| VCYT | Veracyte, Inc. | 72% | Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply with these requirements could substantially harm our business. Certain of our produc… |
| WAT | Waters Corporation | 72% | Reciprocal relationship from WAT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from WAT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from WAT graph:… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HUMA | Humacyte, Inc. | 90% | Reciprocal relationship from HUMA graph: We source bioprocess solutions, including culture media and decellularization buffers, from a division of Thermo Fisher Scientific |
| PCVX | Vaxcyte, Inc. | 90% | Reciprocal relationship from PCVX graph: In September 2025, we also entered into a master services agreement with Patheon Manufacturing Services LLC, part of Thermo Fisher Scientific (collectively, “… |
| TECH | Bio-Techne Corporation | 90% | Reciprocal relationship from TECH graph: we sell through a distribution agreement with Thermo Fisher Scientific |
| AZTA | Azenta, Inc. | 72% | Reciprocal relationship from AZTA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from AZTA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from AZTA gra… |
| DEO | Diageo plc | 72% | the responsible use of emerging technologies such as generative artificial intelligence (AI). These include comprehensive frameworks such as the EU’s General Data Protection Regulation (GDPR), the EU… |
| DEO | Diageo plc | 72% | Reciprocal relationship from DEO graph: Reciprocal relationship from TMO graph: Reciprocal relationship from DEO graph: Reciprocal relationship from TMO graph: the responsible use of emerging technol… |
| GH | Guardant Health, Inc. | 72% | Reciprocal relationship from GH graph: r therapy selection, that sell molecular diagnostic tests for cancer to physicians and have or may develop tests that compete with our tests. In addition, we ar… |
| HRMY | Harmony Biosciences Holdings, Inc. | 72% | Reciprocal relationship from HRMY graph: (“API”). ● Corden Pharma Chenôve SAS, a full-service contract development and manufacturing organization (“CDMO”) manufactures our API. ● Procos, S.p.A. opera… |
| IDXG | Interpace Biosciences, Inc. | 72% | Reciprocal relationship from IDXG graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IDXG graph: tests from sole suppliers. We also purchase components used in our collection… |
| IMTX | Immatics N.V. | 72% | Reciprocal relationship from IMTX graph: Reciprocal relationship from TMO graph: Reciprocal relationship from IMTX graph: A”) with Patheon UK Limited (“Patheon”), a subsidiary of Thermo Fisher Scient… |
| IONS | Ionis Pharmaceuticals, Inc. | 72% | Reciprocal relationship from IONS graph: vestigators, contract research organizations and other third-party service providers to conduct our clinical studies for our medicines and expect to continue … |
| MEDP | Medpace Holdings, Inc. | 72% | Reciprocal relationship from MEDP graph: d and disciplined approach facilitates strong account evaluation, which results in increased focus by the sales team, the management of sales force effectiven… |
| MXCT | MaxCyte, Inc. | 72% | Reciprocal relationship from MXCT graph: doption of our products. If these KOLs, institutions and companies do not adopt our products for any reason, including those listed above, acceptance and adop… |
| PACB | Pacific Biosciences of California, Inc. | 72% | Reciprocal relationship from PACB graph: Reciprocal relationship from TMO graph: Reciprocal relationship from PACB graph: Reciprocal relationship from TMO graph: Reciprocal relationship from PACB gra… |
| RGEN | Repligen Corporation | 72% | Reciprocal relationship from RGEN graph: uct categories as well as several large companies, including Danaher Corporation (Cytiva), Thermo Fisher Scientific Inc., MilliporeSigma and Sartorius. Many o… |
| SUPN | Supernus Pharmaceuticals, Inc. | 72% | Reciprocal relationship from SUPN graph: hat used in Phase 2 clinical trials, nor do we have plans to develop our own manufacturing operations in the foreseeable future to support Phase 3 clinical tr… |
| SVRA | Savara Inc. | 72% | Reciprocal relationship from SVRA graph: Reciprocal relationship from TMO graph: Reciprocal relationship from SVRA graph: primary and secondary drug substance manufacturing partners. The primary drug… |
| TWST | Twist Bioscience Corporation | 72% | Reciprocal relationship from TWST graph: Reciprocal relationship from TMO graph: Reciprocal relationship from TWST graph: Reciprocal relationship from TMO graph: Reciprocal relationship from TWST gra… |
| VCYT | Veracyte, Inc. | 72% | Reciprocal relationship from VCYT graph: Reciprocal relationship from TMO graph: Reciprocal relationship from VCYT graph: y requirements, which may be subject to change, and our failure to comply wit… |
| WAT | Waters Corporation | 72% | Reciprocal relationship from WAT graph: rs continuously introduce new products and have instrument businesses that are generally more diversified than the Company’s business. Some competitors have gr… |
| ABOUT-THERMO-FISHER-SCIENTIFIC-THERMO-FISHER-SCI | ABOUT-THERMO-FISHER-SCIENTIFIC-THERMO-FISHER-SCI | 62% | . As previously announced, the acquisition is expected to contribute $0.45 of adjusted earnings per share (EPS) 1 in the first year after close. Details on the positive impact on Thermo Fisher’s 2026… |
| NORDIC-CAPITAL-NOVO-HOLDINGS | NORDIC-CAPITAL-NOVO-HOLDINGS | 62% | . As previously announced, the acquisition is expected to contribute $0.45 of adjusted earnings per share (EPS) 1 in the first year after close. Details on the positive impact on Thermo Fisher’s 2026… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TMO-DEBT | Debt stack $43.2B | 90% | Market cache reports total debt of $43.2B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TMO-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 2594 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 2 | |
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 100.00 | 2 | |
| ACET | Adicet Bio, Inc. | 100.00 | 2 | |
| GRAL | GRAIL, Inc. | 100.00 | 2 | |
| BIO | Bio-Rad Laboratories, Inc. | 100.00 | 2 | |
| SUPN | Supernus Pharmaceuticals, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| RGEN | Repligen Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| DTIL | Precision BioSciences, Inc. | 100.00 | 2 | |
| DEO | Diageo plc | 100.00 | 2 | ['customer'] |
| PSNL | Personalis, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| BCYC | Bicycle Therapeutics plc | 100.00 | 2 | |
| BHPLF | BHP Group Limited | 100.00 | 1 | ['spend'] |
| AUTL | Autolus Therapeutics plc | 100.00 | 2 | |
| SVRA | Savara Inc. | 100.00 | 1 | ['customer'] |
| IMO | Imperial Oil Limited | 100.00 | 2 | |
| DGX | Quest Diagnostics Incorporated | 100.00 | 2 | |
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| GDTC | CytoMed Therapeutics Limited | 100.00 | 2 |